Bristol Myers Squibb (BMY)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
$64.19+4.02%
Close 2026-11-04 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
QuarterlyIQ Insights · BMY
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 17.3% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -2.3% |
Growth built into the price is above our model estimate.
The price assumes 19.6 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 10 industry peers · Company calendar date is not available
Why it matters: Generic pressure cut Legacy Portfolio sales in Q2. Eliquis growth helped offset that pressure in Q3.
Worry ifIn a quarter, Eliquis sales fall below $4.69 billion worldwide. Legacy Portfolio sales also fall from a year earlier.
Less concerning ifEliquis sales stay at or above $4.69 billion worldwide. Legacy Portfolio sales stay flat or grow from a year earlier.
Why it matters: BMS raised its 2026 revenue range twice this year. Meeting the new floor would show that growth held up.
Supportive ifBMS reports 2026 revenue of at least $49.75 billion, within its latest $49.75 billion to $50.25 billion range.
Worry ifBMS reports 2026 revenue below $49.75 billion or lowers the latest revenue range.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$123 on $10,000 · ±1.2% | How much price usually moves either way. |
| Bad day | $254 loss on $10,000 · 2.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,677 loss on $10,000 · 16.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.